Long‐term efficacy and safety of bexarotene for Japanese patients with cutaneous T‐cell lymphoma: The results of a phase 2 study (B‐1201). Issue 7 (15th May 2019)

• Record Type: Journal Article
• Authors: Hamada, Toshihisa; Tokura, Yoshiki; Sugaya, Makoto; Ohtsuka, Mikio; Tsuboi, Ryoji; Nagatani, Tetsuo; Kiyohara, Eiji; Tani, Mamori; Setoyama, Mitsuru; Matsushita, Shigeto; Kawai, Kazuhiro; Yonekura, Kentaro; Saida, Toshiaki; Iwatsuki, Keiji
• Is Part Of: Journal of dermatology. Volume 46:Issue 7(2019)
• Page Start: 557
• Page End: 563
• Publication Date: 2019-05-15
• Subjects: adverse event -- bexarotene -- cutaneous T‐cell lymphoma -- mycosis fungoides -- objective response rate; Dermatology -- Periodicals; Dermatology -- Japan -- Periodicals; Skin -- Diseases -- Periodicals; 616.5005
• DOI: 10.1111/1346-8138.14923
• Languages: English
• ISSNs: 0385-2407

Abstract

Abstract: The present study (B‐1201 clinical trial) was conducted as a multicenter, open‐label, single‐arm phase II study to evaluate the long‐term safety, tolerability and efficacy of bexarotene. This study enrolled 10 Japanese adults aged more than 20 years with cutaneous T‐cell lymphoma (CTCL) who completed the 24‐week study period of the B‐1101 trial. The objective response rate (ORR) was 53.8% (95% confidence interval, 25.1–80.8). In the early stage (IB), the ORR was 60% (3/5 cases). In the advanced stage (IIB and IIIA), the ORR was 57.1% (4/7 cases). The median time to response was 58 days (range, 27–168). The median treatment duration was 380 days (range, 33–1674). The median duration of response (DOR) could not be reached during the study period. The longest DOR reached 1618 days at the end of the B‐1201 trial. Nine patients (56.3%) in the full analysis set (FAS) population experienced dose reduction of bexarotene. Common drug‐related adverse events in the FAS population included hypothyroidism (93.8%), hypertriglyceridemia (81.3%), hypercholesterolemia (81.3%), leukopenia (68.8%) and neutropenia (56.3%). Dose‐limiting toxicity (DLT) was present in five (38.5%) of the 13 patients in the 300 mg/m 2 cohort. Of the five patients, four developed grade 3 neutropenia and one developed grade 4 hypertriglyceridemia. All DLT cases recovered after the discontinuation of bexarotene. None of the five patients discontinued this trial because of DLT. The B‐1201 trial shows the long‐term safety of oral bexarotene for Japanese patients with CTCL, despite frequent dose reduction.